Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Meningioma

Meningioma

Subtypes of Meningioma

Intracranial meningioma 1

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Meningioma

10 trials tracked for Meningioma: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 12 citations.

10Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 6 Other / NA 2
  1. Phase 3 Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma Completed · 12 cited
  2. Phase 3 Magnesium and Intraoperative Blood Loss in Meningioma Surgery Completed
  3. Phase 2 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed
  4. Phase 2 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Completed
  5. Phase 2 Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) Completed
  6. Phase 2 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed
Show 4 more trials
  1. Phase 2 Monthly SOM230C for Recurrent or Progressive Meningioma Completed
  2. Phase 2 T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Completed
  3. N/A Molecular-Guided Therapy for Childhood Cancer Completed
  4. N/A Stereotactic Body Radiotherapy for Spine Tumors Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Meningioma: what the trials found

In a phase 3 trial involving Gleolan, the percentage of participants with at least one indeterminate tissue or unexpected fluorescent end of surgery (EOS) tissue where Gleolan-induced PpIX fluorescence status was consistent with histology was 60.2% (p<0.0001) 1.

In a phase 3 trial involving a magnesium group, there were no statistically significant differences observed in intraoperative blood loss (510 vs 500; p=0.315), intraoperative packed red cell (PRC) transfusion (2 vs 1; p=0.270), or postoperative MOCA scores (23 vs 25; p=0.299) 2.

For the clinician treating this condition

  • Gleolan demonstrated a statistically significant rate of consistency between PpIX fluorescence and histology in identifying indeterminate tissue or unexpected EOS tissue 1.
  • The magnesium group showed no significant differences in blood loss, PRC transfusion requirements, or postoperative MOCA scores compared to the control 2.

AI synthesis of 2 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Symptomatic radiation necrosis occurs in 5.7% of intracranial brachytherapy patients
Oncology Meta-analysis
Symptomatic radiation necrosis occurs in 5.7% of intracranial brachytherapy patients Brachytherapy for brain tumors: 5.7% risk of radiation necrosis
This meta-analysis of 3666 patients undergoing intracranial brachytherapy for glioma, brain metastases, or meningioma found a pooled inciden…
About 1 in 18 patients who get internal radiation for brain tumors develop symptomatic radiation necrosis, a new analysis finds.
Jun 18, 2026
Particle embolization reduces operative complications compared to liquid agents in meningioma preoperative embolization
Oncology Meta-analysis
Particle embolization reduces operative complications compared to liquid agents in meningioma preoperative embolization Particle embolization lowers complication rates compared to liquid agents for meningioma surgery
This systematic review and meta-analysis evaluated particle versus liquid embolic agents in 1827 patients undergoing preoperative embolizati…
A large review of 1,827 patients found that using particle embolization significantly reduced the risk of complications compared to liquid a…
Jun 1, 2026
Systematic review and meta-analysis of proton therapy for intracranial meningioma reports pooled outcomes
Oncology Meta-analysis
Systematic review and meta-analysis of proton therapy for intracranial meningioma reports pooled outcomes Proton therapy for brain tumors shows strong control with fewer side effects
This systematic review and meta-analysis of 1,431 adult meningioma patients treated with proton therapy found a pooled complication rate of …
Proton therapy offers effective tumor control with fewer side effects for patients with brain meningiomas, especially those near sensitive a…
May 9, 2026
VLSM analysis of 350 meningioma resections links tumor location to histology, symptoms, and surgical outcomes
Oncology Cohort
VLSM analysis of 350 meningioma resections links tumor location to histology, symptoms, and surgical outcomes Brain tumor location patterns linked to symptoms and surgical outcomes in study
A retrospective, single-center cohort of 350 patients who underwent meningioma resection found that voxel-based lesion symptom mapping (VLSM…
Brain tumor location in the brain is linked to specific symptoms and how well surgery removes the growth, according to a new study.
Frontiers Apr 2, 2026

Questions about Meningioma

How does tumor location affect surgery outcomes and symptoms for a Meningioma?

The location of a meningioma significantly impacts the specific symptoms a patient experiences and determines the complexity of the surgery required.

Full answer →
Are there fewer surgical complications when using particle embolization for a Meningioma?

Research indicates that using particle embolization for a meningioma is associated with a significantly lower incidence of overall operative complications compared to liquid agents.

Full answer →